DEF: Praxis Precision Medicines Announces 2025 Annual Meeting and Provides Corporate Update

Praxis Precision Medicines reports on a year of growth and execution, highlighting progress in advancing its pipeline of neurological disorder treatments and outlining key milestones for 2025 and beyond.

Summary

• Praxis Precision Medicines had a year of growth in 2024, advancing its assets for neurological disorders.
• The company is sufficiently funded entering 2025 and is confident in expanding its pipeline candidates.
• Key upcoming milestones include those for vormatrigine, a potential best-in-class treatment for adult epilepsy.
• Phase 2 proof of concept study results for vormatrigine in epilepsy patients with photo-paroxysmal response showed 100% of patients responding.
• The ENERGY program, including the EMPOWER observational study with over 3,000 epilepsy patients, is ongoing.
• Two efficacy trials for vormatrigine, RADIANT and POWER1, are expected to generate topline results this year.
• POWER2, the final study in the ENERGY program, is expected to begin in the second half of 2025.
• Relutrigine data in SCN2A GOF and SCN8A DEEs showed efficacy in seizure reduction and gains in alertness and communication.
• A registrational cohort 2 for EMBOLD in SCN2A and SCN8A DEEs is underway, with topline results anticipated no later than the first half of 2026, followed by a potential NDA filing in 2026.
• The EMERALD study will evaluate relutrigine for broader DEE diagnoses in 2025.
• The registrational trial design for EMBRAVE3 for elsunersen is finalized, with enrollment planned for mid-2025.
• Topline results for the second cohort of EMBRAVE are expected in the first half of 2026.
• Three preclinical antisense oligonucleotide programs within the Solidus TM platform are expected to nominate candidates during 2025.
• An interim analysis of Study 1 of the Essential3 program evaluating ulixacaltamide for essential tremor recommended stopping the study for futility.
• Despite the futility recommendation, both Study 1 and Study 2 of the Essential3 program will continue to completion, with topline results expected in the third quarter of 2025.
• The next 12-18 months are expected to be catalyst-rich, with topline readouts, initiation of registrational studies, and acceleration of pipeline candidates.
• The Annual Meeting of Stockholders will be held on June 26, 2025, at 9:00 a.m. Eastern Time online.

Sentiment

Score: 7

Explanation: The document presents a mixed sentiment. There are positive developments in the epilepsy pipeline, but the futility recommendation for the essential tremor program tempers the overall outlook. The company's strong financial position and upcoming catalysts contribute to a moderately positive sentiment.

Positives

• Praxis is advancing its pipeline of neurological disorder treatments.
• Vormatrigine has the potential to be best-in-class in adult epilepsy.
• Relutrigine data showed efficacy in seizure reduction and gains in alertness and communication in SCN2A GOF and SCN8A DEEs.
• EMBRAVE3 enrollment for elsunersen is planned for mid-2025.
• Three preclinical antisense oligonucleotide programs are expected to nominate candidates during 2025.
• The next 12-18 months are expected to be catalyst-rich for Praxis.

Negatives

• Study 1 of the Essential3 program evaluating ulixacaltamide for essential tremor was recommended to be stopped for futility.

Risks

• The Essential3 program's Study 1 futility recommendation raises concerns about ulixacaltamide's efficacy for essential tremor.
• Clinical trial outcomes are uncertain, and topline results may not be positive.
• Regulatory approvals are not guaranteed, and NDA filings may be delayed.
• The company's financial performance depends on the successful development and commercialization of its pipeline candidates.

Future Outlook

The next 12-18 months are set to be the most catalyst-rich in Praxis' history, with topline readouts across epilepsy and essential tremor programs, the initiation of multiple registrational studies, and continued acceleration of pipeline candidates.

Management Comments

• 2024 was a year of notable growth and execution for our company.
• We entered 2025 sufficiently funded and with increased confidence in our ability to expand the value proposition of our patient-guided pipeline candidates.
• We are looking forward to the upcoming milestones for vormatrigine, which has the potential to be best-in-class in adult epilepsy.
• Thank you for your continued investment in Praxis and for your support of our patient-centric mission.

Industry Context

Praxis is operating in the competitive field of neurological disorders, where there is a high unmet need for effective treatments. The company's focus on rare and prevalent neurological disorders positions it to address a broad market. The futility recommendation for ulixacaltamide highlights the challenges in developing treatments for essential tremor, a condition with limited therapeutic options.

Comparison to Industry Standards

• The 100% patient response rate in the Phase 2 proof of concept study for vormatrigine in epilepsy patients with photo-paroxysmal response is a notable result compared to existing epilepsy treatments.
• The company's focus on human genetics to generate a neurology pipeline is aligned with industry trends in precision medicine.
• The decision to continue both studies in the Essential3 program despite the futility recommendation for Study 1 is a strategic choice, potentially driven by the advanced state of enrollment and the substantial unmet need in essential tremor.
• Other companies in the epilepsy space include UCB, Takeda, and Eisai.
• Companies developing treatments for essential tremor include Acadia Pharmaceuticals and Biohaven Pharmaceuticals.

Related Party Transactions

• In December 2018, Praxis entered into an agreement with RogCon Inc., pursuant to which Praxis agreed to advance RogCon a deposit of up to $1.0 million related to the cooperation and license agreement described in our 2024 Annual Report.
• In September 2019, Praxis entered into a cooperation and license agreement with RogCon further described in our 2024 Annual Report under BusinessLicense Agreements.
• Alex Nemiroff, our General Counsel and Corporate Secretary, is a co-founder and Chief Executive Officer of RogCon.

Stakeholder Impact

• Positive clinical trial results and regulatory approvals would benefit patients with neurological disorders.
• The company's financial performance impacts shareholders.
• Employees are affected by the company's compensation and benefit programs.
• The company's relationships with suppliers and partners are important for its operations.

Next Steps

• Generate topline results for RADIANT and POWER1 efficacy trials for vormatrigine this year.
• Initiate POWER2 study in the second half of 2025.
• Continue registrational cohort 2 for EMBOLD, with topline results anticipated no later than the first half of 2026.
• Initiate the EMERALD study in 2025.
• Start enrolling in EMBRAVE3 in mid-2025.
• Generate topline results for the second cohort of EMBRAVE in the first half of 2026.
• Nominate candidates for three preclinical antisense oligonucleotide programs during 2025.
• Complete both Study 1 and Study 2 of the Essential3 program, with topline results expected in the third quarter of 2025.

Key Dates

Keywords

Praxis Precision Medicines, epilepsy, neurological disorders, vormatrigine, relutrigine, elsunersen, essential tremor, ulixacaltamide, clinical trials, pipeline, SCN2A, SCN8A, DEE, NDA, EMBOLD, EMBRAVE, ENERGY, EMPOWER, RADIANT, POWER1, POWER2, EMERALD, EMBRAVE3, Essential3, Solidus, Cerebrum